February 18, 2009 -- Zogenix, Inc., a private, specialty pharmaceutical company, announced that the U.S. FDA has provided a target date of July 15, 2009 for completion of its review of the NDA for Sumavel DosePro(sumatriptan injection) needle-free delivery system.
The details can be read here.
No comments:
Post a Comment